BIBLIOGRAFÍA 1) Brange J. Insulin preparations. En: Galenius of insulin. Berlin, Alemania. Spring-Verlag, 1987; pág. 17-73. 2) Barnett A, Owens D. Insulin analogues.The Lancet 1997; 349: 47-51. 3) Holleman F, Koestra J. Insulin lispro. New Engl J Med 1997; 337: 176-183. 4) Kang S, Brange J, Burch A. Subcutaneous insulin Absortion explained by insulin’s physicochemical properties. Diabetes care 1991; 14: 942-7. 5) Bolli G, Di Marchi R, Koivisto V y col. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999; 42: 1151-67. 6) Dreyer K. The bioactivity of Insulin Analogues from in vitro Receptor Binding to in vivo glucose uptake. Diabetes Metabol Rev 1992; 8: 259-286. 7) Wolpert H, Slieker L, Sundell K, King G. Identification of an insulin analog with enhanced growth effect in aortic smooth muscle cells. Diabetes 1990; 39 [Supl 1]: 140A. 8) Torlone E, Fanelli C, Bolli G. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [ Lys (B28), Pro (B29)] in IDDM. Diabetologia 1994; 37: 713-20. 9) Anderson J, Brunelle R, Koivisto V, Vignati L, and the Multicenter Insulin Lispro Study Group. Reduction of postprandial hyperglycemia and frecuency of hypoglycemia in IDDM patients on Insulin-analog treatment. Diabetes 1997; 46: 265-70. 10) Braak E, Woodworth J, Kurts D, y col. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996; 19: 1437-1440. 11) Fineberg N, Fineberg S, Anderson J, Hufferd S. Immunologic effects of insulin lispro [Lys(B28), Pro (B29) Human Insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996; 45: 1750-4. 12) Takewii A, Throckmorton DC, y col. Periodic high extracellular glucose enhances production of collagens III and IV by mesangial cells. Am J Physiol 1995; 268: F13- F19. 13) Grunwald JE, BrucknerAJ, y col. Diabetic glycemic control and retinal blood flow. Diabetes 1999; 39: 602-7. 14) Schernthaner G, Wein W, Birkett M. Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patiens. Diabetes Care 1998; 21: 570-3. 15) Burge M, Castillo K, Schade D. Meal composition in a determinant of lispro-induced hypoglycemia in DIIM. Diabetes Care 1997; 20: 152-5. 16) Vignati L, Anderson J, Brunelle R, Jefferson F. Improvement of glycemic control with the rapidly absorbed lispro insulin analog in type I diabetes. Diabetologia 1994; 37 [Supl 1]: 301. 17) Ronemaa T, Viikarii J. Reducing snacks when switching from conventional soluble to lispro insulin treatment: effects on glycemic control and hypoglycaemia. Diabetic Med 1998; 15: 601-7. 18) Renner R, Peutzner A, Trautman M, Harzer O. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Diabetes Care 1999; 22: 784-7. 19) Schmau S, König A, Landgraf R. Human insulin analogue[Lys (B28), Pro (B29)]: The ideal pump insulin? Diabetic Med 1998; 15: 247-49. 20) Guerci B, Meyer L, Salle A, Charrie A, Drouin P. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. J Clin Endocrinol Metabol 1999; 84: 2673-8. 21) Attia N, Jones T, Holcombe J, Tamborlane W. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care 1998; 21: 817-21. 22) Zinman B, Tildesley H, Chiasson J, Tsui E, Strack T. Insulin lispro in CSII. Diabetes 1997; 46: 440-3. 23) Ooi Ch, Mullen P, Williams G. Insulin lispro. The ideal pump insulin for patients with severe hypoglycemic unawareness? Diabetes Care 1999; 22: 1598-9. 24) Fineberg S, Fineberg N, Anderson Hufferd S. Comparative immunogenicity fo lyspro (B28,29) human insulin analog between type 1 and type 2 patients. Diabetologia 1994; 37 [Supl. 1]: 646. 25) Brunelle R, Anderson J, Vignati L. Decreased rate of hypoglycemia in association with improved metabolic control. Diabetologia 1994; 37 [Supl. 1]: 300. 26) Heller S, Amiel S, Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemiaduring intensified insulin therapy. Diabetes Care 1999; 22: 1607-11. 27) Melki V, Renard E, Tauber J. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 1998; 21: 977-82. 28) Howorka K, Schulsche C. Algorithm adaptation under functional insulin treatment during transfer from regular to insulin lispro. Diabetes, Nutr Metabol1998; 11: 266-72. 29) Ebeling P, Bolli G, Koivisto V, y col. Long term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insuline at mealtime. Diabetes Care 1999; 22: 468-77. 30) Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Bolli G, y col. Long term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insuline at meal-time. Diabetes care 1999; 22: 468-77. 31) Ciofetta M, Lalli C, Del Sindaco P, Bolli. G. Contribution of postprandial vs interprandial blood pressure to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999; 22: 795-9. 32) Torlone E, Pampanelli S, Bolli G. Effects of the short–acting insulin analog [Lys (B28), Pro (B29)] on postprandial blood glucose control in IDDM. Diabetes Care 1996; 19: 945-52. 33) Del Sindaco P, Ciofetta M, Bolli G. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabetic Med 1998; 15: 592-600. 34) Pampanelli S, Torlone E, Bolli G. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic ß-cell function. Diabetes Care 1995; 18: 1452-9. 35) Lahtela, Knip M, Salmi J. Severe antibody–mediated human insulin resistance: successful treatment with the insulin analog lispro. Diabetes Care 1997; 20: 71-73. 36) Abraham M, Sharafi B, Khardori R. Lispro in the treatment of insulin allergy. Diabetes Care 1999; 22: 1916-7. 37) Henrichs H, Unger H, Trautmann. Treatment of a case of severe subcutaneous insulin resistance using the insulin analogue Lys (B28) Pro (B29) for facilitated subcutaneous absorption. Diabetologia 1994; 37[ Sup 1]: 647. 38) Henrichs H, Unger H, Trautmann M. Severe insulin resistance treated with insulin lispro. The Lancet 1996; 348:1248. 39) Perez A, Caixas A, De Leiva A. Insulin lispro and regular insulin have a similar effect on lypolitic activities and VLDL composition in NIDDM. Diabetologia 1994; 37 [Sup 1]: 649. 40) Nielsen F, Jorgensen L, Parving H. Long term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia 1995; 38: 592-8. 41) Tuominen J, Karonen S, Bolli G. Exercise–induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia 1995; 38: 106-11. 42) Letiexhe M, Rutters A, Schmitt H. (Lys (B28), Pro (B29)) Human insulin: patiens treated with lyspro vs human insulin: quality of life assessment. Diabetologia 1994; 37 [Supl. 1]: 648. 43) Jovanovic L. Retinopathy risk: what is responsible? Hormones, hyperglycemia, or humalog? Diabetes Care 1999; 22: 846-7. 44) Bhattacharyya A, Vice P. Insulin lispro, pregnancy and retinopathy. Diabetes Care 1999; 22: 2101-2. 45) Chew EY, Mills JL, Metzger BE, Remaley NA, Jovanovic-Peterson L, y col. National institute of child health and human development diabetes in early pregnancy study: Metabolic control and progression of retinopathy: The diabetes in early pregnancy study. Diabetes Care 1995; 18: 631-37. 46) Jovanovic L, Ilic S, Bastyr E. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 1999; 22: 1422-7. 47) Anderson J, Brunelle R, Di Marchi R. Mealtime Treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin dependent diabetes mellitus. Arch Intern Med 1997; 157: 1250-5. 48) Vantyghem M, Vigouroux C, Capeau J. Late–onset lipoatrophic diabetes. Diabetes Care 1999; 22: 1374-6. 49) Aisenpreis U, Pfutzner A, Jehle PM. Pharmacokinetics and pharmacodynamics of insulin lispro compared with regular insulin in haemodialisis patients with diabetes mellitus. Neprol Dialysis Transpl 1999; 14 [Supl 4]: 5-6. 50) Raskin P, Guthrie R, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23: 583-7. 51) Frier BM, Ewing FM, Lindholm A, Hylleberg B, Kanc K. Symptomatic and counterregulatory hormonal responses to acute hypoglycaemia induced by insulin aspart and soluble human insulin in type 1 diabetes. Diabetes Metabol Res Rev 2000; 16: 262-8. 52) Lindholm A, Mc Ewen J, Rus A. Improved postprandial glycemic control with insulin aspart. Diabetes Care 1999; 22: 801-5. 53) Roach P, Yue L. The humalog Mix 25 study group improved postprandial glycemic control during treatment with humalog Mix 25, a novel protamine–based insulin lispro formulation. Diabetes Care 1999; 22: 1258-61. 54) Heise T, Weyer C, Heinemann I. Time–action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998; 21: 800-3. 55) Rave K, Heinemann L, Heise T. Premixed formulations of insulin lispro: Activity profiles in type 1 diabetic patients. Diabetes Care 1999; 22: 865-6. 56) Jorgensen S, Vaag A, Markussen J. NovoSol basal: pharmacoKinetics of a novel soluble long acting insulin analogue. BMJ 1989; 299: 415-9. 57) Buse J. Insulin glargine (HOE 901) first responsabilities: understanding the data and ensuring safety. Diabetes Care 2000; 23: 576-8. 58) Mohn A, Strang S, Dunger D. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care 2000; 23: 557-9. 59) Dreyer M, Pein M, Schmidth Chr. Heidtmann comparison of the pharmacokinetics & dynamics of Gly (A21)-Arg(B31, B32)-human insulin (HOE 71GT) with NPH-insulin following subcutaneous injection by using euglycaemic clamp technique. Diabetologia 1994; 37 [Supl. 1]: 303. 60) Owens D, Coates P, Kurzhals R. Pharmacokinetics of I125–labeled insulin glargine (HOE 901) in healthy men. Diabetes Care 2000; 23: 813-9. 61) Pieber T, Jolchine I, Derobert E. The european study group of HOE 901 in type 1 diabetes. Diabetes Care 2000; 23: 157-62. 62) Berchtold H, Hilgenfeld R. Binding of phenol to R6 insulin hexamers. Biopolymers 1999; 51: 165-72. 63) Ratner R, Hirsch I, Wilson C. U.S. Study group of insulin glargine in type 1 diabetes. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000; 23: 639-43. 64) Shojaee-Moradie F, Eckey H, Jones R. Novel hepatoselective insulin analogues: studies with covalently linked thyroxyl-insulin complexes. Diabetic Med 1998; 15: 928-36. 65) Thyers S, Yakubu F, Chen V. Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes 1997; 46: 637-42. 66) Hamilton-Wessler M, Ader M, Bergman R. Mechanism of protacted metabolic effects of fatty acid acylated insulin NN304, in dogs: retention of NN304 by albumin. Diabetologia 1999; 42: 1254-63. 67) Heinemann L, Sinha K, Weyer C. Time section profile of the soluble, fatty acid acylated, long-acting insulin. Diabetic Med 1999; 16: 332-8. 68) Huang YD, Yang SZ, Feng YJ. An insulin analogue with gamma–amino butyric acid substitution for A13 Leu-A14 Tyr. Peptide Research 1999; 54: 18-22.
|
